» Articles » PMID: 31173492

Embryonic Stem Cell Microenvironment Suppresses the Malignancy of Cutaneous Melanoma Cells by Down-regulating PI3K/AKT Pathway

Overview
Journal Cancer Med
Specialty Oncology
Date 2019 Jun 8
PMID 31173492
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant cancer cells engage in a dynamic reciprocity with the tumor microenvironment (TME) that promotes tumor growth, development, and resistance to therapy. Early embryonic blastocyst microenvironments can reverse the tumorigenic phenotype of malignant cancer cells via ameliorating of TME. It is potential to apply embryonic stem cell (ESC) microenvironment to suppress the malignant behaviors of cancer cells. This study aimed to investigate a better method and the mechanism of ESC microenvironment supplied by ESCs on suppressing the malignancy of cutaneous melanoma cells. Cutaneous melanoma cell line A2058 were cultured and divided into four groups: (a) A2058-only (Control); (b) A2058 and ESCs continuously co-cultured (Group One); (c) A2058 co-cultured with daily refreshed ESCs (Group two); (d) Group one with VO-Ohpic, inhibitor of PTEN (VO-Ohpic Group). The results showed that, compared to control group, A2058 cells in group one exhibited decreased cellular proliferation, migration, invasiveness and vasculogenic mimicry concomitant with an increase in cell apoptosis, accompanied by down-regulation of PI3K/AKT pathway. Besides, the above mentioned anti-tumor effects on A2058 cells were significantly enhanced in group two but statistically weakened after administration of VO-Ohpic compared to group one. We demonstrate that ESC microenvironment reduces the malignancy of A2058 by down-regulating PI3K/AKT pathway. Notably, such anti-tumor effects can be enhanced by appropriately increasing the quality and quantity of ESCs in co-culture system. Our results suggest that ESC microenvironment could be an effective and safe approach to treating cancer.

Citing Articles

The roles of cancer stem cells and therapeutic implications in melanoma.

Mu X, Zhou Y, Yu Y, Zhang M, Liu J Front Immunol. 2024; 15:1486680.

PMID: 39611156 PMC: 11602477. DOI: 10.3389/fimmu.2024.1486680.


Therapeutic role of PTEN in tissue regeneration for management of neurological disorders: stem cell behaviors to an in-depth review.

Li Y, Ma R, Hao X Cell Death Dis. 2024; 15(4):268.

PMID: 38627382 PMC: 11021430. DOI: 10.1038/s41419-024-06657-y.


Single-Cell Transcriptomics for Unlocking Personalized Cancer Immunotherapy: Toward Targeting the Origin of Tumor Development Immunogenicity.

Khodayari S, Khodayari H, Saeedi E, Mahmoodzadeh H, Sadrkhah A, Nayernia K Cancers (Basel). 2023; 15(14).

PMID: 37509276 PMC: 10377122. DOI: 10.3390/cancers15143615.


Human embryonic stem cells exert antitumor effects on prostate cancer cells in a co-culture microenvironment.

Yang X, Lu Y, Kuang Q, Wu Y, Tan X, Lan J Front Oncol. 2023; 13:1164250.

PMID: 37313467 PMC: 10258316. DOI: 10.3389/fonc.2023.1164250.


The embryonic stem cell microenvironment inhibits mouse glioma cell proliferation by regulating the PI3K/AKT pathway.

He X, Liu J, Wang X, Liu T, Yang L, Li C Transl Cancer Res. 2022; 10(1):487-498.

PMID: 35116278 PMC: 8799092. DOI: 10.21037/tcr-20-3408.


References
1.
Cao Z, Bao M, Miele L, Sarkar F, Wang Z, Zhou Q . Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer. 2013; 49(18):3914-23. DOI: 10.1016/j.ejca.2013.07.148. View

2.
Niwa H, Burdon T, Chambers I, Smith A . Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998; 12(13):2048-60. PMC: 316954. DOI: 10.1101/gad.12.13.2048. View

3.
Relation T, Dominici M, Horwitz E . Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells. Stem Cells. 2017; 35(5):1123-1130. DOI: 10.1002/stem.2596. View

4.
Sauter E, Yeo U, Von Stemm A, Zhu W, Litwin S, Tichansky D . Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002; 62(11):3200-6. View

5.
Steeg P . Angiogenesis inhibitors: motivators of metastasis?. Nat Med. 2003; 9(7):822-3. DOI: 10.1038/nm0703-822. View